Generic Name and Formulations:
Alitretinoin 0.1%; gel.
Indications for PANRETIN:
Cutaneous lesions of AIDS-related Kaposi's sarcoma (KS).
Apply twice daily to lesions (avoid mucous membranes and normal skin); do not occlude; may increase to 3–4 times daily as tolerated. Reduce frequency or suspend treatment if local toxicity occurs.
Not for use when systemic KS therapy required. Avoid sun, UV light. Flammable. Pregnancy (Cat.D), nursing mothers: not recommended.
Increases DEET toxicity (avoid).
Photosensitivity, rash, pruritus, pain, exfoliative dermatitis, paresthesia, edema.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Differences in Efficacy and Tolerability of ADHD Medications Across Age Groups
- Rapid Cycling Bipolar Disorder Associated With ADHD and Female Gender
- Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia
- Oxycontin's Maker Now Selling Drug to Curb Opioid Addiction
- Symptom Trajectories Vary According to Language Development in Autism
- Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations
- Selective Serotonin Reuptake Inhibitors May Increase Risk for Suboptimal Fetal Growth
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Prenatal Insecticide Exposure in Mother May Be Linked to Risk for Autism in Children